SBScott D. Boden

Scott D. Boden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott D. Boden has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contributors

    by Frank L. Acosta, Mir H. Ali, Edward R. Anderson, Paul A. Anderson, Paul M. Arnold, Edward C. Benzel, Sigurd Berven, Scott D. Boden, Christopher M. Bono, Ali Bydon, et al.

  • Whatʼs New in Spine Surgery

    by Keith H Bridwell, Paul A Anderson, Scott D Boden, Alexander R Vaccaro, Jeffrey C Wang


  • Whatʼs New in Spine Surgery

    by Keith H. Bridwell, Paul A Anderson, Scott D. Boden, Alexander R. Vaccaro, Jeffrey C. Wang

    Many controversies still exist with regard to the surgical treatment of cervical spine pathology. The role of allograft, autograft, plate fixation, and bone morphogenetic protein is not entirely clear. There is still debate about the surgical treatment of myelopathy anteriorly as opposed to posteriorly. Clearly, there is substantial anatomic variation in the location of the vertebral artery. Disc arthroplasty for the cervical spine continues to appear to be a viable option for patients with single-level pathology. ### Anterior Cervical Fusion Despite interest in motion preservation, cervical fusion remains a common and highly successful surgical approach for the treatment of radiculopathy and myelopathy. Recently reported clinical outcomes following single-level fusion have shown that a substantial reduction in pain and disability occurs in about 90% of cases. Improvement in overall health-related quality of life, as measured with the Short Form-36 (SF-36), was substantial compared with that occurring after total hip or total knee arthroplasty. Multivariable analysis showed that the presence of litigation and narcotic use were negative predictors of success, whereas high levels of preoperative disability and sensory loss were positive predictors. Following allograft and plate fixation of a single level, fusion success occurred in 95% of the patients as reported in three randomized clinical trials. To enhance fusion success, other biologic and reconstructive measures have been utilized. Pulsed electromagnetic field stimulation following anterior fusion showed improved fusion success as compared with controls at six months but no difference at twelve months and showed no improvement in any clinical outcome parameters. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an alternative, especially in cases of multilevel fusion, after which the pseudarthrosis rate is known to be increased. The United States Food and Drug Administration (FDA) recently warned against the off-label use of rhBMP-2 in the cervical spine because of severe inflammatory reactions causing dysphagia, hematoma, and airway …


  • Whatʼs New in Spine Surgery

    by Keith H. Bridwell, Paul A Anderson, Scott D. Boden, Alexander R. Vaccaro, Jeffrey C. Wang

    Trends in the treatment of the cervical spine include the evaluation of new technology as well as a focus on the understanding of old concepts and postulates. The results of randomized controlled trials of cervical arthroplasty are now available, and this procedure appears promising. ### Anatomy To safely perform many of the complex surgical procedures that involve the use of screw fixation, an understanding of the surgical anatomy of the cervical spine is essential. Osseous and vascular anomalies in the cervical spine that place the vertebral artery at risk during surgery have been identified. The vertebral artery normally enters the spine at C6 and ascends in the foramen transversarium until C2, where it turns, first laterally and then cranially, and ascends into the C1 foramen transversarium. It then loops medially, lying on the superior surface of the C1 arch. Approximately 15 mm from the midline, it turns anteriorly, enters the spinal canal, and passes through the foramen magnum. In the subaxial spine in a small number of patients, the artery can enter at C7 (or, more commonly, it can become ectatic with age) and can intrude into the vertebral body, placing it at risk during corpectomy. This finding is easily recognized on anteroposterior radiographs or axial computed tomography and magnetic resonance images. The vertebral artery may pass too far rostrally and medially within C2, thinning the pedicle so that C1-C2 transarticular and C2 pedicle screws cannot be placed safely. This occurs in as many as 15% of cases. As an alternative, screw purchase can be obtained in the C2 lamina, thereby avoiding vertebral artery risk. Biomechanical studies comparing this method with other C2 screw constructs have shown similar fixation strength. Lateral mass fixation into C1 is gaining popularity. Screw position is critical, as rostrally angled screws can penetrate the atlanto-occipital articulation and …


  • AOA Symposium

    by Alan S Hilibrand, Kurt P Spindler, Scott D Boden


  • Whatʼs New in Spine Surgery

    by Keith H. Bridwell, Paul A. Anderson, Scott D. Boden, Alexander R. Vaccaro, Jeffrey C. Wang

    The results of randomized controlled trials of several cervical arthroplasty devices are becoming available and are the focus of much attention. At the same time, secondary outcomes are being analyzed that may address socioeconomic concerns about the costs and observable benefits of arthroplasty. Since the introduction of a validated outcome tool to measure swallowing dysfunction, researchers have more critically analyzed postoperative dysphagia. With the continued expansion of the use of cervical laminoplasty, methods to reduce complications continue to be explored. ### Disc Arthroplasty Disc arthroplasty is currently undergoing rigorous clinical testing, and the outcomes of this procedure are being compared with those of fusion in randomized controlled trials. The inclusion criteria are single level radiculopathy or myelopathy, failure of nonoperative management, adult age, and the absence of significant instability or severe spondylosis or facet disease. Full reports on these trials are not yet available. However, pooled results from several investigation sites have been presented for three different prostheses. All studies have shown significant improvements in outcome measures for both fusion and experimental groups. With arthroplasty, the mean range of motion has increased by 1° to 2° and the rates of complications related to the procedure have been low, with no differences compared with controls. Two studies evaluating titanium polyurethane and stainless steel metal-on-metal prostheses demonstrated that the pooled site outcomes were significantly better for the arthroplasty group than for the fusion group with regard to pain, disability, and overall success. Six-year outcomes from Europe are encouraging, with patients maintaining clinical improvement and motion. Adjacent-segment disease appears to progress in patients with preexisting disease but not in its absence. From outside the United States, there have been case reports of complications, including the late development of central stenosis secondary to osteophyte formation, fracture of a vertebral body during insertion, spontaneous fusion, expulsion of the …


  • WHATʼS NEW IN SPINE SURGERY

    by Keith H Bridwell, Paul A Anderson, Scott D Boden, Alexander R Vaccaro, Jeffrey C Wang


  • What's New in Spine Surgery

    by Keith H. Bridwell, Paul A. Anderson, Scott D. Boden, Alexander R. Vaccaro, Jeffrey C. Wang

    An increasing number of prospective studies have established the efficacy of many cervical spine procedures. At the same time, complications and morbidity have been critically analyzed. Several of these studies regarding anterior fusion and laminoplasty will be reviewed. ### Outcomes Long-term follow-up with use of validated instruments and strict radiographic criteria are effective for evaluating surgical results. The Cervical Spine Research Society prospectively followed 181 patients for two years to assess the influence of plates on outcomes. In patients with single-level fusions, the use of a plate was associated with a significantly higher rate of successful fusion (94% compared with 73%). Rigid and translational plates were associated with better results than plates that only allowed the toggle of screw heads. Other studies of intervertebral fusion devices have demonstrated conflicting results. Carbon fiber-reinforced spacers used as stand-alone devices had results similar to allografts, whereas tantalum mesh implants had poor results that necessitated the discontinuation of a randomized study. Pulsed electromagnetic field stimulation has been shown to induce fusion in the lumbar spine and the healing of extremity nonunions. In a prospective, randomized study, pulsed electromagnetic field stimulation was associated with higher rates of successful cervical fusion (84% compared with 69%), although no significant differences in functional outcomes were noted. Interestingly, successful fusion, either with or without pulsed electromagnetic field stimulation, was significantly correlated with good clinical outcomes. Controversies still remain with regard to the approach (i.e., anterior or posterior) for treatment of cervical spondylotic myelopathy. In a randomized study comparing corpectomy and autograft fusion with laminoplasty, no differences were noted with regard to the rate of neurologic recovery or the range of motion of the neck. However, both groups had significant improvement in neurologic function. Axial pain was greater in the laminoplasty group. Complications in the anterior treatment group included dysphagia and pseudarthrosis, …


  • Ne-Osteo Bone Growth Factor for Posterolateral Lumbar Spine Fusion: Results From a Nonhuman Primate Study and a Prospective Human Clinical Pilot Study

    by Scott D. Boden, Dieter Grob, Christopher Damien

    Prospective animal and human clinical pilot trial. The purpose of this study was to determine and test the dose of Ne-Osteo growth factor extract and carrier required for consistent radiographic bone induction in humans. Preclinical studies have demonstrated that Ne-Osteo, an extract-containing bone morphogenetic proteins, was successful at generating spine fusion in rabbits and rhesus monkeys. Consistent fusions have yet to be achieved in nonhuman primates and humans. Adult rhesus monkeys underwent single-level posterolateral intertransverse lumbar arthrodesis with either 3.0 mg (N = 4), 5.0 mg (N = 4), 12.5 mg (N = 4), or 25 mg (N = 4) of Ne-Osteo per side. Animals were killed after 24 weeks. In the human clinical trial, 22 patients (18 females, 4 males) had lumbar spinal stenosis and/or spondylolisthesis requiring spine arthrodesis. To minimize patient risk of nonunion, patients received autogenous bone graft from the posterior iliac crest on one side and Ne-Osteo growth factor on the other. The dose was 12.5 mg, 25 or 50 mg, or 25 mg Ne-Osteo per side performed in the three phases, respectively. Three of four monkeys that received 12.5 mg Ne-Osteo per side and four of four that received 25 mg per side achieved solid fusions. In phase I of the human clinical trial, two of six patients showed radiographic bone induction (plain radiograph, CT scans—blindly evaluated) on the Ne-Osteo side (12.5-mg dose). In phase II, both sides were graded as fused in five of six patients. Although graded as fused, the 6-month scans demonstrated a ring of new bone with the center filling in slower (12–24 mo) than was predicted by nonhuman primate studies. As a result, phase III carrier was designed to have a more porous/open early fusion mass than with the dense DBM paste (used in phase I and II) by mixing in local bone or cancellous allograft chips. Results using the 25- and 50-mg doses were the same, so 25 mg was used in phase III. In phase III, 9 of 10 autograft were fused by 12 months. Five of five patients with Ne-Osteo plus local bone and four of five with allograft chips were fused by 6 months. The one patient in this group that did not heal on either the autograft or the Ne-Osteo side was a smoker. A graft composite of Ne-Osteo bone growth factor with human DBM with or without cancellous allograft or local bone autograft was capable of achieving a contiguous spine fusion mass in 15 of 16 patients at a dose of at least 25 mg per side. This result was comparable with the results using iliac crest autograft (94%) in this side-by-side model. These results warrant confirmation in a definitive trial using Ne-Osteo on both sides of the spine and thus avoiding the need for iliac crest bone graft harvest.